3B
3B Blackbio DX Ltd (3BBLACKBIO)
₹1,305.10
Mkt cap
₹1,134 Cr
P/E ratio
19.40
P/B
3.22
Div yield
0.38%
ROE
19.80%
ROCE
25.50%
EPS (TTM)
₹67.27
Book value
₹405
52W range
1,085–1,740
Sector
Healthcare
Price history
Previous close
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products [1]
NSE 3BBLACKBIOBSE 532067
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−24.99% from high₹1,305
₹1,085+20.29% from low₹1,740
Current
₹1,305.10
Prev close
₹1,316.60
Day
−0.87%
Price performance
1D
+0.25%
1W
−1.61%
1M
−2.18%
3M
+14.66%
6M
+9.83%
1Y
—
YTD
+0.25%
Financials
Revenue, profit & margin
P/E ratio
19.4×
3BBLACKBIO is 48% below the sector median of 37.0×
3BBLACKBIO19.4×
Sector median37.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19 | 18 | 23 | 19 | 29 | 25 | 22 | 22 | 34 | 50 | 35 | 33 | 48 | |
| YoY Sales growth | +11% | +20% | +27% | +36% | +52% | +44% | -2% | +14% | +16% | +98% | +57% | +51% | +42% | |
| Expenses | 11 | 9 | 13 | 8 | 13 | 10 | 15 | 10 | 19 | 29 | 27 | 25 | 27 | |
| Operating Profit | 8 | 9 | 10 | 11 | 16 | 15 | 8 | 12 | 15 | 22 | 8 | 9 | 21 | |
| OPM % | 41% | 50% | 43% | 56% | 55% | 59% | 35% | 53% | 43% | 43% | 24% | 25% | 44% | |
| Other Income | 3 | 3 | 4 | 4 | 3 | 3 | 5 | 4 | 6 | 6 | 10 | 6 | 5 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 1 | 1 | |
| Profit before tax | 10 | 11 | 14 | 14 | 19 | 18 | 13 | 16 | 20 | 27 | 15 | 13 | 24 | |
| Tax % | 26% | 24% | 36% | 21% | 23% | 24% | 36% | 20% | 23% | 16% | 33% | 32% | 26% | |
| Net Profit | 8 | 9 | 9 | 11 | 15 | 13 | 8 | 13 | 15 | 22 | 10 | 9 | 18 | |
| EPS in Rs | 10.46 | 10.16 | 10.33 | 12.97 | 17.07 | 15.61 | 9.79 | 14.67 | 17.14 | 25.32 | 11.14 | 11.10 | 20.74 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202640.95%Promoter
Promoters40.95%
FIIs2.46%0.04
DIIs2.33%0.18
Public54.26%0.14
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lal Pathlabs | ₹1,965.40 | 54.48 | 32,989 | 0.71% | 194 | +28.75% | 874 | +19.61% | 28.00% |
| Vijaya Diagnost. | ₹1,533.60 | 77.55 | 15,796 | 0.13% | 59 | +37.41% | 255 | +26.71% | 20.53% |
| Metropolis Healt | ₹564.30 | 50.74 | 11,711 | 0.35% | 75 | +43.04% | 497 | +15.76% | 17.81% |
| Thyrocare Tech. | ₹503.60 | 45.81 | 8,025 | 1.85% | 15 | −11.56% | 271 | +25.07% | 35.38% |
| Nephrocare Health Services | ₹653.00 | 51.43 | 6,589 | 0.00% | 34 | +454.07% | 303 | +23.47% | 15.34% |
| Suraksha Diagno. | ₹348.05 | 43.34 | 1,813 | 0.14% | 15 | +66.96% | 99 | +25.84% | 17.29% |
| Krsnaa Diagnost. | ₹511.30 | 16.42 | 1,659 | 0.39% | 25 | +8.95% | 240 | +31.17% | 12.71% |
| 3B Blackbio | ₹1,321.60 | 19.35 | 1,134 | 0.38% | 18 | +21.01% | 48 | +42.42% | 25.48% |
| Median: 16 Co. | ₹367.27 | 36.96 | 1,004 | 0.07% | 15 | +10.52% | 83 | +24.27% | 21.66% |
Filings
Annual reports15
Concall transcripts50
Credit ratings4
Announcements5
Disclosure Under Regulation 30 Of SEBI (LODR)Regulations, 2015 18 Nov - Coris BioConcept to acquire 100% of Bilex SRL for €274,817, securing Gembloux facility and €140,000 annual savings.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 16 Nov - 3B BlackBio DX to hold virtual one-on-one meeting with Fortuna Asset Managers LLP on 21 November 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Nov - Newspaper clipping of extract of financial results for quarter and half ended 30th September, 2026Financial Results For The Quarter And Half Year Ended 30Th September, 2026 13 NovFinancial Results For The Quarter And Half Year Ended 30Th September, 2026 13 Nov



